聚乙二醇化精氨酸脱亚胺酶联合顺铂和培美曲塞治疗精氨基琥珀酸合成酶1缺陷型胸部肿瘤的1期剂量递增研究
该1期剂量递增研究纳入9例未接受化疗的精氨基琥珀酸合成酶1(ASS1)缺陷型恶性胸膜间皮瘤(MPM)或非小细胞肺癌(NSCLC)患者,接受每周ADI-PEG 20(18、27或36 mg/m²)联合每3周培美曲塞500 mg/m²和顺铂75 mg/m²。未报告剂量限制性毒性,9例中7例(78%)达到部分缓解。作者推荐未来研究剂量为每周ADI-PEG 20 36 mg/m²联合每3周顺铂75 mg/m²和培美曲塞500 mg/m²。
要点
- 在ASS1缺陷型MPM或NSCLC患者中,ADI-PEG 20联合顺铂和培美曲塞未报告剂量限制性毒性。
- 9例患者中7例(78%)观察到部分缓解,包括3例肉瘤样或双相型MPM。
- 作者推荐未来研究剂量为每周ADI-PEG 20 36 mg/m²联合每3周顺铂75 mg/m²和培美曲塞500 mg/m²。
核心结论
- 靶点结合导致的精氨酸耗竭在整个治疗期间得以维持,且未报告剂量限制性毒性。
- 在ASS1缺陷型癌症的生物标志物选择患者中,观察到临床活性,包括预后不良肿瘤患者。
- 作者推荐未来研究剂量为每周ADI-PEG 20 36 mg/m²联合每3周顺铂75 mg/m²和培美曲塞500 mg/m²。
研究设计与样本
- 采用3+3+3剂量递增研究设计,纳入9例未接受化疗的患者(5例MPM,4例NSCLC)。
- 患者接受每周ADI-PEG 20剂量为18 mg/m²、27 mg/m²或36 mg/m²,联合每3周培美曲塞500 mg/m²和顺铂75 mg/m²(最多6个周期)。
- 达到疾病稳定或更好的患者可继续ADI-PEG 20单药治疗直至疾病进展或退出。
- 不良事件按常见不良事件评价标准4.03版评估,并评估药效学和免疫原性。
- 肿瘤反应按RECIST 1.1版(NSCLC)或改良RECIST标准(MPM)评估。
主要发现
- 未报告剂量限制性毒性;报告的38起不良事件中9起(均为1级或2级)与ADI-PEG 20相关。
- 循环精氨酸浓度迅速下降,瓜氨酸水平升高,两者变化持续至18周。
- 9例患者中7例(78%)观察到部分缓解,包括3例肉瘤样或双相型MPM。
关键数值与推荐
- ADI-PEG 20剂量递增水平为18 mg/m²、27 mg/m²或36 mg/m²,每周给药。
- 培美曲塞500 mg/m²和顺铂75 mg/m²每3周给药,最多6个周期。
- 部分缓解定义为按RECIST 1.1版(NSCLC)或改良RECIST标准(MPM)评估。
临床怎么用
- 作者推荐未来研究剂量为每周ADI-PEG 20 36 mg/m²联合每3周顺铂75 mg/m²和培美曲塞500 mg/m²。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC). Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naïve patients (five MPM, four NSCLC) received weekly ADI-PEG 20 doses of 18 mg/m2, 27 mg/m2, or 36 mg/m2, together with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 which were given every three weeks (maximum of six cycles). Patients achieving stable disease or better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal. Adverse events were assessed by Common Terminology Criteria for Adverse Events version 4.03, and pharmacodynamics and immunogenicity were also evaluated. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for NSCLC and by modified RECIST criteria for MPM. Results No dose-limiting toxicities were reported; nine of 38 reported adverse events (all grade 1 or 2) were related to ADI-PEG 20. Circulating arginine concentrations declined rapidly, and citrulline levels increased; both changes persisted at 18 weeks. Partial responses were observed in seven of nine patients (78%), including three with either sarcomatoid or biphasic MPM. Conclusion Target engagement with depletion of arginine was maintained throughout treatment with no dose-limiting toxicities. In this biomarker-selected group of patients with ASS1-deficient cancers, clinical activity was observed in patients with poor-prognosis tumors. Therefore, we recommend a dose for future studies of weekly ADI-PEG 20 36 mg/m2 plus three-weekly cisplatin 75 mg/m2 and pemetrexed 500 mg/m2.
引用
- Beddowes E, Spicer J, Chan PY, et al. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J Clin Oncol. 2017. PMID: 28388291. doi:10.1200/JCO.2016.71.3230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。